MIT科技评论发布了2024年35岁以下创新者名单，其中9人在生物技术领域工作1。这些年轻科学家的研究涵盖多个关键领域，从解决全球健康问题到开发前沿治疗手段。
坦桑尼亚科学家帕斯卡尔·基加（Paschal Kija）开发了一款名为Mkanda Salama的医疗设备，成本仅为70美元，能在20分钟内有效阻止73%患者的产后出血1。鉴于产后出血在坦桑尼亚约占孕产妇死亡的29%，这项创新具有重要的公共卫生意义1。
在基因治疗领域，莎拉·格兰迪内特（Sarah Grandinette）为患有罕见遗传病的婴儿KJ设计了个性化基因编辑疗法，该患儿在7个月大时接受治疗后恢复良好1。同时，尤安成（Yuancheng Lu）的细胞逆龄疗法在2020年研究中使失明小鼠恢复了视力，Life Biosciences公司版本已于6月对首位志愿者进行了用药测试1。
在人工智能应用方面，塞缪尔·金（Samuel King）利用生成式AI设计了噬菌体的新遗传蓝图，AI设计的病毒在实验中能够自我复制并感染其他细菌1。
MIT Technology Review has recognized nine biotech researchers under age 35 as innovators shaping the field's future, highlighting breakthrough advances in medical devices, gene therapy, cellular regeneration, and artificial intelligence.1
Among the featured scientists is Paschal Kija, who developed the Mkanda Salama device to combat postpartum hemorrhage at a cost of just $70 per unit.1 The device successfully halts bleeding within 20 minutes in 73% of patients, addressing a critical public health challenge in regions like Tanzania, where postpartum hemorrhage accounts for approximately 29% of maternal deaths.1
Sarah Grandinette has pioneered personalized gene editing therapy for infants with rare genetic disorders.1 Her approach proved effective for a patient named KJ, who received treatment at seven months old and showed strong recovery outcomes.1 Meanwhile, Yuancheng (Ryan) Lu's cellular rejuvenation technology achieved a landmark result in 2020 by restoring vision to blind mice.1 Life Biosciences, his company, administered the treatment to the first volunteer in June.1
Samuel King has leveraged generative artificial intelligence to design novel genetic blueprints for bacteriophages, with the AI-designed viruses demonstrating the ability to self-replicate and infect bacteria in laboratory experiments.1 These innovations collectively demonstrate how the next generation of biotech researchers is developing practical solutions to longstanding medical challenges.
评论
还没有评论，欢迎留下第一条。